department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Lucentis · pharmadog

pharmadog
drugs
Lucentis

drug

patient view →

ranibizumab

Marketedupdated 2mo ago

by Genentech Inc

Approved

community read0 votes

indications

investigational

Diabetic Macular Edema

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Lucentis

generic

ranibizumab

indication

Choroidal Neovascularization

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 58m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

🐶 often sniffed alongside

top 8

tagApproval18 co-mentions · 9 sources
drugBYOOVIZ16 co-mentions · 8 sources
drugranibizumab SR14 co-mentions · 14 sources
drugranibizumab biosimilar13 co-mentions · 13 sources
companySamsung Bioepis Co Ltd8 co-mentions · 8 sources
companyXbrane Biopharma AB5 co-mentions · 5 sources
tagOphthalmology5 co-mentions · 5 sources
tagBiosimilar5 co-mentions · 5 sources

Trials studying ranibizumab

phase3A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)completedn=400
phase3A Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Choroidal Neovascularization Secondary to Pathologic Myopiacompletedn=280
phase3Extension Study for the Port Delivery System With Ranibizumab (Portal)recruitingn=1,000
phase3Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)recruitingn=561
phase2A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edemacompletedn=394
phase2Study of Zifibancimig in Participants With Neovascular Age-related Macular Degenerationactive not recruitingn=177
phase3Pivotal 1 Study of ABBV-RGX-314 (Also Known as RGX-314) Gene Therapy Administered Via Subretinal Delivery One Time in Participants With nAMDactive not recruitingn=671
phase4A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)recruitingn=188

more trials →